Ab Initio Pharma to Support Advancement of NBX-200 Following Positive Phase 1 Results

Ab Initio Pharma congratulates Neurala Biosciences on reporting positive Phase 1 data for its second-generation DMT–harmala candidates NBX-100 and NBX-200. The study demonstrated strong pharmacodynamic activity and favourable tolerability in healthy volunteers.

Full details of the announcement can be accessed via Neurala’s press release on BioSpace

Following these encouraging results, Ab Initio Pharma will support the continued clinical advancement of NBX-200 through GMP manufacturing and development activities aligned with regulatory requirements for future studies.

This collaboration highlights Ab Initio’s capability in compliant clinical supply manufacture and complex CNS product development.